Astellas banks on existing data in surprise US re-filing of once-daily tacrolimus
This article was originally published in Scrip
Executive Summary
After mulling on the quiet for several years whether to go ahead or not, Astellas has finally filed a US NDA for the once-daily capsule formulation of its immunosuppressant tacrolimus.